Although the lipogenic potential of GIP alone is under debate, coactivation of GLP‐1R and GIPR is an attractive prospect in the treatment of T2DM and perhaps obesity (Figure 2).125. This evidence concerns the gene GIP and obesity due to melanocortin 4 receptor deficiency.